Song Yao1, Ting-Yuan David Cheng1,2, Ahmed Elkhanany3, Li Yan4, Angela Omilian1, Scott I Abrams5, Sharon Evans5, Chi-Chen Hong1, Qianya Qi4, Warren Davis1, Song Liu4, Elisa V Bandera6, Kunle Odunsi5, Kazuaki Takabe7, Thaer Khoury8, Christine B Ambrosone1. 1. Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 2. Department of Epidemiology, University of Florida, Gainesville, FL, USA. 3. Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 4. Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 5. Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 6. Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, The State University of New Jersey, New Brunswick, NJ, USA. 7. Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 8. Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Abstract
BACKGROUND: Blacks tend to have a stronger inflammatory immune response than Whites. We hypothesized that racial differences in host immunity also manifest in the tumor microenvironment, constituting part of a distinct aggressive tumor biology underlying higher mortality in Black women. METHODS: Pathological and gene expression profiling approaches were used for characterizing infiltrating immune cells in breast tumor microenvironment from 1315 patients from the Women's Circle of Health Study. Racial differences in tumor immune phenotypes were compared, with results validated in a publicly accessible dataset. Prognostic associations of immune phenotypes were assessed in 3 independent cohorts. RESULTS: We found marked and consistent differences in tumor immune responses between Black and White patients. Not only did tumors from Blacks display a stronger overall immune presence but also the composition and quality of immune infiltrates differed, regardless of tumor subtypes. Black patients had a stronger CD4+ and B-cell response, and further, a more exhausted CD8+ T-cell profile. A signature indicating a higher ratio of exhausted CD8+ T cells to total CD8+ T cells (ExCD8-r) was consistently associated with poorer survival, particularly among hormone receptor-positive patients. Among hormone receptor-negative patients, combinations of the absolute fraction of CD8+ T cells and ExCD8-r signature identified the CD8lowExCD8-rhigh subgroup, the most prevalent among Blacks, with the worst survival. CONCLUSIONS: Our findings of a distinct exhausted CD8+ T-cell signature in Black breast cancer patients indicate an immunobiological basis for their more aggressive disease and a rationale for the use of immune checkpoint inhibitors targeting the exhaustion phenotype.
BACKGROUND: Blacks tend to have a stronger inflammatory immune response than Whites. We hypothesized that racial differences in host immunity also manifest in the tumor microenvironment, constituting part of a distinct aggressive tumor biology underlying higher mortality in Black women. METHODS: Pathological and gene expression profiling approaches were used for characterizing infiltrating immune cells in breast tumor microenvironment from 1315 patients from the Women's Circle of Health Study. Racial differences in tumor immune phenotypes were compared, with results validated in a publicly accessible dataset. Prognostic associations of immune phenotypes were assessed in 3 independent cohorts. RESULTS: We found marked and consistent differences in tumor immune responses between Black and White patients. Not only did tumors from Blacks display a stronger overall immune presence but also the composition and quality of immune infiltrates differed, regardless of tumor subtypes. Black patients had a stronger CD4+ and B-cell response, and further, a more exhausted CD8+ T-cell profile. A signature indicating a higher ratio of exhausted CD8+ T cells to total CD8+ T cells (ExCD8-r) was consistently associated with poorer survival, particularly among hormone receptor-positive patients. Among hormone receptor-negative patients, combinations of the absolute fraction of CD8+ T cells and ExCD8-r signature identified the CD8lowExCD8-rhigh subgroup, the most prevalent among Blacks, with the worst survival. CONCLUSIONS: Our findings of a distinct exhausted CD8+ T-cell signature in Black breast cancer patients indicate an immunobiological basis for their more aggressive disease and a rationale for the use of immune checkpoint inhibitors targeting the exhaustion phenotype.
Authors: R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi Journal: Ann Oncol Date: 2014-09-11 Impact factor: 32.976
Authors: Mikhail Binnewies; Edward W Roberts; Kelly Kersten; Vincent Chan; Douglas F Fearon; Miriam Merad; Lisa M Coussens; Dmitry I Gabrilovich; Suzanne Ostrand-Rosenberg; Catherine C Hedrick; Robert H Vonderheide; Mikael J Pittet; Rakesh K Jain; Weiping Zou; T Kevin Howcroft; Elisa C Woodhouse; Robert A Weinberg; Matthew F Krummel Journal: Nat Med Date: 2018-04-23 Impact factor: 53.440
Authors: Foluso O Ademuyiwa; Stephen B Edge; Deborah O Erwin; Heather Orom; Christine B Ambrosone; Willie Underwood Journal: Cancer Res Date: 2010-12-06 Impact factor: 12.701
Authors: Kristin Wallace; David N Lewin; Shaoli Sun; Clayton M Spiceland; Don C Rockey; Alexander V Alekseyenko; Jennifer D Wu; John A Baron; Anthony J Alberg; Elizabeth G Hill Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-05-16 Impact factor: 4.254
Authors: Kathy S Albain; Joseph M Unger; John J Crowley; Charles A Coltman; Dawn L Hershman Journal: J Natl Cancer Inst Date: 2009-07-07 Impact factor: 13.506
Authors: Song Yao; Chi-Chen Hong; Edward A Ruiz-Narváez; Sharon S Evans; Qianqian Zhu; Beverly A Schaefer; Li Yan; Marie V Coignet; Kathryn L Lunetta; Lara E Sucheston-Campbell; Kelvin Lee; Elisa V Bandera; Melissa A Troester; Lynn Rosenberg; Julie R Palmer; Andrew F Olshan; Christine B Ambrosone Journal: PLoS Genet Date: 2018-06-07 Impact factor: 5.917
Authors: Shawn D Blackburn; Haina Shin; W Nicholas Haining; Tao Zou; Creg J Workman; Antonio Polley; Michael R Betts; Gordon J Freeman; Dario A A Vignali; E John Wherry Journal: Nat Immunol Date: 2008-11-30 Impact factor: 25.606
Authors: Damali N Martin; Brenda J Boersma; Ming Yi; Mark Reimers; Tiffany M Howe; Harry G Yfantis; Yien Che Tsai; Erica H Williams; Dong H Lee; Robert M Stephens; Allan M Weissman; Stefan Ambs Journal: PLoS One Date: 2009-02-19 Impact factor: 3.240
Authors: Melissa A Troester; Katherine A Hoadley; Alina M Hamilton; Amber N Hurson; Linnea T Olsson; Andrea Walens; Joseph Nsonwu-Farley; Erin L Kirk; Yara Abdou; Stephanie M Downs-Canner; Jonathan S Serody; Charles M Perou; Benjamin C Calhoun Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-07-01 Impact factor: 4.090
Authors: Vesal Yaghoobi; Myrto Moutafi; Thazin Nwe Aung; Vasiliki Pelekanou; Sanam Yaghoubi; Kim Blenman; Eiman Ibrahim; Ioannis A Vathiotis; Saba Shafi; Anup Sharma; Tess O'Meara; Aileen I Fernandez; Lajos Pusztai; David L Rimm Journal: Breast Cancer Res Date: 2021-12-14 Impact factor: 6.466
Authors: Sung Jun Ma; Lucas M Serra; Brian Yu; Mark K Farrugia; Austin J Iovoli; Han Yu; Song Yao; Oluwadamilola T Oladeru; Anurag K Singh Journal: Cancers (Basel) Date: 2022-01-21 Impact factor: 6.639